A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies. Issue 2 (30th January 2019)

• Record Type: Journal Article
• Authors: Nanni, Laura; Morigi, Alice; Casadei, Beatrice; Broccoli, Alessandro; Stefoni, Vittorio; Argnani, Lisa; Cavo, Michele; Zinzani, Pier Luigi
• Is Part Of: Hematological oncology. Volume 37:Issue 2(2019)
• Page Start: 202
• Page End: 204
• Publication Date: 2019-01-30
• Subjects: experimental drugs -- prolonged disease control -- Sézary syndrome; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2573
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16‐year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Patient refused to undergo allogeneic stem cell transplantation. After eleven lines of therapeutic approaches, the patient is in very good partial response and free of therapy at the latest available follow‐up.